Eventide
Investing that makes the world rejoice®
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Eventide Information
Geographic Data
Address: One International Place
City: Boston
State: MA
Zip: 02110
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
2,661,748Website Global Rank
6,617Website Monthly Traffic
Twitter Followers
Description
Eventide Asset Management, LLC is a Boston-based investment adviser practicing "investing that makes the world rejoice®." Founded in 2008, Eventide&s;s vision is to serve individuals, financial advisors, and institutions by providing high-performance investments that we believe create compelling value for the global common good.
Contact Phone:
+18777713836
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2022 | Beta Bionics | Series C | 0 |
| 7/2018 | Pliant Therapeutics | Series B | 0 |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 4/2018 | Magenta Therapeutics | Series C | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 4/2021 | Biosplice Therapeutics | Venture Round | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 11/2020 | Prometheus Biosciences | Equity | 130M |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 4/2021 | Arch Oncology | Series C | 0 |
| 9/2020 | Casma Therapeutics | Series B | 50M |
| 10/2021 | Roivant Sciences | Post-IPO Equity | 0 |
| 5/2021 | Flare Therapeutics | Series A | 82M |
| 6/2020 | Freeline | Series C | 80M |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 12/2021 | Freenome | Series D | 300M |
| 4/2019 | Satsuma Pharmaceuticals | Series B | 0 |
| 1/2019 | Beta Bionics | Series B | 63M |
| 7/2019 | Beta Bionics | Series B | 63M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 2/2019 | Peloton Therapeutics | Series E | 0 |
| 6/2020 | Goldfinch Biopharma | Series B | 100M |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 6/2021 | Kojin Therapeutics | Series A | 60M |
| 1/2022 | Korro Bio | Series B | 0 |
| 7/2020 | Praxis Precision Medicines | Series C | 0 |
| 7/2021 | Turnstone Biologics | Series D | 0 |
| 3/2023 | Flare Therapeutics | Series B | 0 |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 3/2020 | Pliant Therapeutics | Series C | 0 |
| 10/2020 | VectivBio | Equity | 110M |
| 7/2020 | Annexon Biosciences | Series C | 100M |
| 1/2022 | Metagenomi | Series B | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 2/2022 | Beta Bionics | Series C | 0 |
| 1/2022 | Metagenomi | Series B | 0 |
| 1/2022 | Korro Bio | Series B | 0 |
| 12/2021 | Freenome | Series D | 0 |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 10/2021 | Roivant Sciences | Post-IPO Equity | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
| 7/2021 | Turnstone Biologics | Series D | 0 |
| 6/2021 | Kojin Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
